Pre-market hot trades in US stocks: Adaptimmune Therap fell 7.58% in pre-market; VivoSim Labs rose 3.91% in pre-market

Popular Pre-Market Trades in U.S. Stocks

Top Gainers in U.S. Pre-Market Trading

SciSparc is up 117.39% in pre-market trading. According to recent key news:

1. On September 17, SciSparc's stock price surged in pre-market trading as AutoMax filed a court motion to suspend the merger process with SciSparc. The court approved this request due to uncertainties in the merger terms, leading to significant stock price fluctuations.

2. On September 16, SciSparc announced that AutoMax submitted a motion to the Jerusalem District Court seeking approval for the merger agreement. The court decided to suspend the process until September 30 due to uncertainties regarding AutoMax's ability to meet the merger conditions.

3. On September 17, SciSparc's trading volume surged to over 21 million shares, far exceeding the three-month daily average of approximately 702,000 shares, indicating a strong market reaction to the merger news.

Vyome is up 65.70% in pre-market trading. According to recent key news:

1. On September 17, Vyome Holdings Inc. released a new business development announcement, driving a significant increase in stock price. The announcement, published via Business Wire, detailed the company's expansion plans into new markets, attracting positive investor attention and resulting in a 65.70% pre-market stock price increase. The market reacted positively to the new business expansion.

CaliberCos is up 46.30% in pre-market trading. Based on recent key news:

1. On September 17, Caliber announced a securities purchase agreement with institutional investors, successfully selling $15.9 million in perpetual convertible preferred stock and launching an ATM equity program. This move provided the company with additional capital, further strengthening its digital asset treasury execution strategy.

2. On September 17, Caliber submitted a supplemental prospectus to the U.S. Securities and Exchange Commission to initiate the ATM program. The program will be based on the company's existing $50 million shelf registration statement, with approximately $10.3 million available in the initial phase.

3. On September 17, Caliber announced that the Series B preferred stock sold could be converted into Caliber common stock at the holder's option at a price of $250 per share. This news boosted market confidence and drove the stock price higher, with increased capital inflow in the digital asset sector